The Commission on Classification and Terminology and the Commission on Epidemiology of the International League Against Epilepsy (ILAE) have charged a Task Force to revise concepts, definition, and classification of status epilepticus (SE). The proposed new definition of SE is as follows: Status epilepticus is a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms, which lead to abnormally, prolonged seizures (after time point t1). It is a condition, which can have long-term consequences (after time point t2), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of seizures. This definition is conceptual, with two operational dimensions: the first is the length of the seizure and the time point (t1) beyond which the seizure should be regarded as “continuous seizure activity.” The second time point (t2) is the time of ongoing seizure activity after which there is a risk of long-term consequences. In the case of convulsive (tonic–clonic) SE, both time points (t1 at 5 min and t2 at 30 min) are based on animal experiments and clinical research. This evidence is incomplete, and there is furthermore considerable variation, so these time points should be considered as the best estimates currently available. Data are not yet available for other forms of SE, but as knowledge and understanding increase, time points can be defined for specific forms of SE based on scientific evidence and incorporated into the definition, without changing the underlying concepts. A new diagnostic classification system of SE is proposed, which will provide a framework for clinical diagnosis, investigation, and therapeutic approaches for each patient. There are four axes: (1) semiology; (2) etiology; (3) electroencephalography (EEG) correlates; and (4) age. Axis 1 (semiology) lists different forms of SE divided into those with prominent motor systems, those without prominent motor systems, and currently indeterminate conditions (such as acute confusional states with epileptiform EEG patterns). Axis 2 (etiology) is divided into subcategories of known and unknown causes. Axis 3 (EEG correlates) adopts the latest recommendations by consensus panels to use the following descriptors for the EEG: name of pattern, morphology, location, time-related features, modulation, and effect of intervention. Finally, axis 4 divides age groups into neonatal, infancy, childhood, adolescent and adulthood, and elderly.
All free recent news, studies, books and guidelines from multiple internet databases and journals on neuroscience, ethics and philosophy in one page
New ILAE Classification System for Seizures
The new International League Against Epilepsy (ILAE) seizure classifications were presented at the American Epilepsy Society conference during the Annual Fundamentals Symposium: The New Definition and Classification of Epilepsy on Friday, December 2, 2016.
The 2017 ILAE Seizure Classifications were created by numerous individuals over the past 12 years, according to the presenter Robert Fisher, MD, PhD, who was also a part of the Seizure Classification and Revision Task Forces for the guidelines.
The classifications were approved by the ILAE just 1 week prior to the presentation. Attendees of the session were the first to see these classifications, highlighting the advantage of attending conferences.
The previous international classifications had been in effect since 1981, but since then, there has been much advancement in the areas of epilepsy treatment and research.
According to the session, there were multiple reasons to revise the classifications. The 1981 classifications made it difficult to classify certain seizures. Furthermore, they did not use consciousness as an aspect of seizures, even though it can help physicians to diagnose epilepsy. In addition, certain important seizure types were not included in the previous classifications, and certain terms were used that are not fully accepted or understood by the public.
The 2017 ILAE Seizure Classifications were created by numerous individuals over the past 12 years, according to the presenter Robert Fisher, MD, PhD, who was also a part of the Seizure Classification and Revision Task Forces for the guidelines.
The classifications were approved by the ILAE just 1 week prior to the presentation. Attendees of the session were the first to see these classifications, highlighting the advantage of attending conferences.
The previous international classifications had been in effect since 1981, but since then, there has been much advancement in the areas of epilepsy treatment and research.
According to the session, there were multiple reasons to revise the classifications. The 1981 classifications made it difficult to classify certain seizures. Furthermore, they did not use consciousness as an aspect of seizures, even though it can help physicians to diagnose epilepsy. In addition, certain important seizure types were not included in the previous classifications, and certain terms were used that are not fully accepted or understood by the public.
Neuropathology of SUDEP - Role of inflammation, blood-brain barrier impairment, and hypoxia
Z Michalak, D Obari, M Ellis, M Thom, SM Sisodiya
Neurology 2017;88:1-11
Using immunohistochemistry, we
investigated the expression of 6 markers (CD163, human leukocyte
antigen–antigen D related, glial fibrillary acid protein, hypoxia-inducible factor-1a
[HIF-1a], immunoglobulin G, and albumin) in the hippocampus, amygdala, and medulla
in 58 postmortem cases: 28 SUDEP (definite and probable), 12 epilepsy controls,
and 18 nonepileptic sudden death controls. A semiquantitative measure of
immunoreactivity was scored for all markers used, and quantitative image
analysis was carried out for selected markers. Immunoreactivity was observed
for all markers used within all studied brain regions and groups.
Immunoreactivity for inflammatory reaction, BBB leakage, and HIF-1a in SUDEP
cases was not different from that seen in control groups. This study represents
a starting point to explore by immunohistochemistry the mechanisms underlying
SUDEP in human brain tissue. Our approach highlights the potential and
importance of considering immunohistochemical analysis to help identify
biomarkers of SUDEP. Our results suggest that with the markers used, there is
no clear immunohistochemical signature of SUDEP in human brain.
Free Full Text Article...
Surgical Treatment of Nonlesional Neocortical Epilepsy. Long-term Longitudinal Study
What are the long-term surgical outcomes and the possible prognostic factors in patients with nonlesional neocortical epilepsy?
In a long-term study that included 109 patients, nearly 60% of patients
with nonlesional neocortical epilepsy achieved long-term freedom from seizure.
Several factors, including localizing patterns in functional neuroimaging,
concordant results in presurgical diagnostic evaluations, and the presence of
aura, were associated favorable surgical outcome.
Patients with nonlesional neocortical epilepsy can be good surgical
candidates, and the presence of predictors of favorable surgical outcome would
help select optimal candidates for surgical treatment.
FARS2 mutation and epilepsy: Possible link with early-onset epileptic encephalopathy.
Cho JS, Kim SH, Kim HY, Chung T, Kim D, Jang S, Lee SB, Yoo SK, Shin J, Kim JI, Kim H, Hwang H, Chae JH, Choi J, Kim KJ, Lim BC
Epilepsy Res. 2016 Dec 02;129:118-124
Early-onset epileptic encephalopathy (EOEE) consists of a heterogeneous group of epilepsy phenotypes. Recent technological advances in molecular biology have also rapidly expanded the genotype of EOEE. Genes involved in diverse molecular pathways, including ion channels, synaptic structure, transcription regulation, and cellular growth, have been implicated in EOEE. Mitochondrial aminoacyl tRNA synthetase, which plays a key role in mitochondrial protein synthesis by attaching 20 different amino acids to the tRNA tail, has been recently linked with the epilepsy phenotype. Here, we report a novel homozygous c.925G>A (G309S) missense mutation in the gene that encodes the human mitochondrial phenylalanyl-tRNA synthetase (FARS2) in four patients from two nonconsanguineous Korean families. All four patients suffered from intractable seizures that started at the age of 3 and 4 months. Seizure types were variable, including infantile spasms and myoclonic seizures, and often prolonged. Although their initial development seemed to be normal, relentless regression after seizure onset occurred in all patients. An etiologic investigation, including brain imaging and metabolic studies, did not reveal a specific etiology. We reviewed the epilepsy phenotypes of six additional FARS2 mutation-positive patients and suggest that FARS2 can be considered one of the genetic causes of EOEE.
Epilepsy Res. 2016 Dec 02;129:118-124
Early-onset epileptic encephalopathy (EOEE) consists of a heterogeneous group of epilepsy phenotypes. Recent technological advances in molecular biology have also rapidly expanded the genotype of EOEE. Genes involved in diverse molecular pathways, including ion channels, synaptic structure, transcription regulation, and cellular growth, have been implicated in EOEE. Mitochondrial aminoacyl tRNA synthetase, which plays a key role in mitochondrial protein synthesis by attaching 20 different amino acids to the tRNA tail, has been recently linked with the epilepsy phenotype. Here, we report a novel homozygous c.925G>A (G309S) missense mutation in the gene that encodes the human mitochondrial phenylalanyl-tRNA synthetase (FARS2) in four patients from two nonconsanguineous Korean families. All four patients suffered from intractable seizures that started at the age of 3 and 4 months. Seizure types were variable, including infantile spasms and myoclonic seizures, and often prolonged. Although their initial development seemed to be normal, relentless regression after seizure onset occurred in all patients. An etiologic investigation, including brain imaging and metabolic studies, did not reveal a specific etiology. We reviewed the epilepsy phenotypes of six additional FARS2 mutation-positive patients and suggest that FARS2 can be considered one of the genetic causes of EOEE.
Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate-A national approach to the evaluation of therapeutic drug monitoring data and clinical outcome.
![]() |
| By Alfie↑↓© (Helmut Schütz) - Own work, CC BY 3.0, https://commons.wikimedia.org/w/index.php?curid=14784996 |
Epilepsy Res. 2016 Dec 05;129:125-131
Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED), still insufficiently studied regarding pharmacokinetic variability, efficacy and tolerability. The purpose of this study was to evaluate therapeutic drug monitoring (TDM) data in Norway and relate pharmacokinetic variability to clinical efficacy and tolerability in a long-term clinical setting in patients with refractory epilepsy.
METHODS: This retrospective observational study included TDM-data from the main laboratories and population data from the Norwegian Prescription Database in Norway, in addition to clinical data from medical records of adult patients using ESL for up to three years, whenever possible.
RESULTS: TDM-data from 168 patients were utilized for assessment of pharmacokinetic variability, consisting of 71% of the total number of patients in Norway using ESL, 2011-14. Median daily dose of ESL was 800mg (range 400-1600mg), and median serum concentration of ESL was 53μmol/L (range 13-132μmol/L). Inter-patient variability of ESL was extensive, with 25-fold variability in concentration/dose ratios. Additional clinical data were available from 104 adult patients out of the 168, all with drug resistant focal epilepsy. After 1, 2 and 3 years follow-up, the retention rate of ESL was 83%, 72% and 64%, respectively. ESL was generally well tolerated as add-on treatment, but sedation, cognitive impairment and hyponatremia were reported. Hyponatremia (sodium <137mmol/L) was present in 36% of the patients, and lead to discontinuation in three.
CONCLUSION: Pharmacokinetic variability of ESL was extensive and the demonstration of usefulness of TDM requires further studies. In patients with drug resistant focal Epilepsy, the high retention rate indicated good efficacy and tolerability. Hyponatremia was observed in one third of the patients. The present results point to a need for individualization of treatment and TDM may be useful.
Investigation of neuronal auto-antibodies in systemic lupus erythematosus patients with epilepsy.
Karaaslan Z, Ekizoğlu E, Tektürk P, Erdağ E, Tüzün E, Bebek N, Gürses C, Baykan B
Epilepsy Res. 2016 Dec 14;129:132-137
Epilepsy is an important feature for neuropsychiatric involvement in systemic lupus erythematosus (SLE) with unknown mechanism. Our aim was to investigate the presence of neuronal auto-antibodies (NAbs) in neuropsychiatric SLE (NPSLE).
METHODS: Eighteen SLE patients (17 females, 1 male) experiencing recurrent seizures were enrolled to this study. Their clinical characteristics, EEG and MRI findings and follow-up information were evaluated from their files. Antibodies against voltage-gated potassium channel (VGKC)-complex antigens, contactin-associated protein-like 2 (CASPR-2), leucine-rich, glioma inactivated 1 (LGI1), glutamic acid decarboxylase (GAD), N-methyl-d-aspartate receptor (NMDA-R), alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptor (AMPA-R) and type B gamma aminobutyric acid receptors (GABAB-R) were screened in the sera of these patients. Moreover, indirect immunohistochemistry and immunocytochemistry tests were performed to reveal neuropil antibodies.
RESULTS: Six out of 18 patients (33.3%) had various forms of NAbs. Among them, one patient had antibodies against GAD, one patient with hippocampal sclerosis on MRI was CASPR-2 antibody positive, whereas the remaining four patients showed hippocampal neuropil staining. We could not find a significant difference between seropositive and seronegative groups, regarding the clinical characteristics, EEG and MRI findings.
CONCLUSION: This study is the first to show hippocampal neuronal staining (4/18) reflecting antibodies against unknown neuronal cell surface antigens in SLE patients with epilepsy, besides the rare occurrence of GAD and CASPR2 antibodies. Further prospective studies are needed to search for new NAbs and uncover their pathogenic role in SLE associated with epilepsy.
Epilepsy Res. 2016 Dec 14;129:132-137
Epilepsy is an important feature for neuropsychiatric involvement in systemic lupus erythematosus (SLE) with unknown mechanism. Our aim was to investigate the presence of neuronal auto-antibodies (NAbs) in neuropsychiatric SLE (NPSLE).
METHODS: Eighteen SLE patients (17 females, 1 male) experiencing recurrent seizures were enrolled to this study. Their clinical characteristics, EEG and MRI findings and follow-up information were evaluated from their files. Antibodies against voltage-gated potassium channel (VGKC)-complex antigens, contactin-associated protein-like 2 (CASPR-2), leucine-rich, glioma inactivated 1 (LGI1), glutamic acid decarboxylase (GAD), N-methyl-d-aspartate receptor (NMDA-R), alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptor (AMPA-R) and type B gamma aminobutyric acid receptors (GABAB-R) were screened in the sera of these patients. Moreover, indirect immunohistochemistry and immunocytochemistry tests were performed to reveal neuropil antibodies.
RESULTS: Six out of 18 patients (33.3%) had various forms of NAbs. Among them, one patient had antibodies against GAD, one patient with hippocampal sclerosis on MRI was CASPR-2 antibody positive, whereas the remaining four patients showed hippocampal neuropil staining. We could not find a significant difference between seropositive and seronegative groups, regarding the clinical characteristics, EEG and MRI findings.
CONCLUSION: This study is the first to show hippocampal neuronal staining (4/18) reflecting antibodies against unknown neuronal cell surface antigens in SLE patients with epilepsy, besides the rare occurrence of GAD and CASPR2 antibodies. Further prospective studies are needed to search for new NAbs and uncover their pathogenic role in SLE associated with epilepsy.
Electrophysiological resting-state biomarker for diagnosing mesial temporal lobe epilepsy with hippocampal sclerosis.
Jin SH, Chung CK
Epilepsy Res. 2016 Nov 23;129:138-145
The main aim of the present study was to evaluate whether resting-state functional connectivity of magnetoencephalography (MEG) signals can differentiate patients with mesial temporal lobe epilepsy (MTLE) from healthy controls (HC) and can differentiate between right and left MTLE as a diagnostic biomarker. To this end, a support vector machine (SVM) method among various machine learning algorithms was employed. We compared resting-state functional networks between 46 MTLE (right MTLE=23; left MTLE=23) patients with histologically proven HS who were free of seizure after surgery, and 46 HC. The optimal SVM group classifier distinguished MTLE patients with a mean accuracy of 95.1% (sensitivity=95.8%; specificity=94.3%). Increased connectivity including the right posterior cingulate gyrus and decreased connectivity including at least one sensory-related resting-state network were key features reflecting the differences between MTLE patients and HC. The optimal SVM model distinguished between right and left MTLE patients with a mean accuracy of 76.2% (sensitivity=76.0%; specificity=76.5%). We showed the potential of electrophysiological resting-state functional connectivity, which reflects brain network reorganization in MTLE patients, as a possible diagnostic biomarker to differentiate MTLE patients from HC and differentiate between right and left MTLE patients.
Epilepsy Res. 2016 Nov 23;129:138-145
The main aim of the present study was to evaluate whether resting-state functional connectivity of magnetoencephalography (MEG) signals can differentiate patients with mesial temporal lobe epilepsy (MTLE) from healthy controls (HC) and can differentiate between right and left MTLE as a diagnostic biomarker. To this end, a support vector machine (SVM) method among various machine learning algorithms was employed. We compared resting-state functional networks between 46 MTLE (right MTLE=23; left MTLE=23) patients with histologically proven HS who were free of seizure after surgery, and 46 HC. The optimal SVM group classifier distinguished MTLE patients with a mean accuracy of 95.1% (sensitivity=95.8%; specificity=94.3%). Increased connectivity including the right posterior cingulate gyrus and decreased connectivity including at least one sensory-related resting-state network were key features reflecting the differences between MTLE patients and HC. The optimal SVM model distinguished between right and left MTLE patients with a mean accuracy of 76.2% (sensitivity=76.0%; specificity=76.5%). We showed the potential of electrophysiological resting-state functional connectivity, which reflects brain network reorganization in MTLE patients, as a possible diagnostic biomarker to differentiate MTLE patients from HC and differentiate between right and left MTLE patients.
Timing of first event in inpatient long-term video-EEG monitoring for diagnostic purposes.
![]() |
| CC BY-SA 2.0, https://commons.wikimedia.org/w/index.php?curid=845554 |
Epilepsy Res. 2016 Dec 14;129:91-94
Long-term video-EEG monitoring (LTM) aims to record the habitual event and is a useful diagnostic tool for neurological paroxysmal clinical events. In our epilepsy monitoring unit (EMU) setting, admissions are usually planned to last up to five days. We ascertained time taken for the recording of a first event and determined correlations between different clinical characteristics and timings.
METHODS: We retrospectively reviewed diagnostic and classification LTM recording performed at a tertiary epilepsy centre.
RESULTS: Sixty-three recordings were reviewed. Most subjects (89%) had events at least once a week prior to admission. In 40 (63%) a habitual event was recorded, mostly (93%) within the first two days. No events were recorded on day four or five. A few characteristics were associated with a trend for events occurring earlier (events more than once a week vs less than once a week, motor symptoms compared with aura or dyscognitive events, and reduction of antiepileptic drugs versus no reduction).
CONCLUSIONS: Our finding suggests that, for diagnostic event recording in people with epilepsy or PNEA, a maximum recording time of three days is sufficient in two thirds of them, if event frequency is at least once a week. In the remaining third, prolonged recording up to five days did not result in capturing a clinical event. For these individuals, shorter admission could be planned, for example for 2days rather than 5days.
Physiological Ripples Associated with Sleep Spindles Differ in Waveform Morphology from Epileptic Ripples.
![]() |
| CC BY-SA 2.0, https://commons.wikimedia.org/w/index.php?curid=845554 |
Int J Neural Syst. 2016 Nov 02;:1750011
High frequency oscillations (HFOs, 80-500[Formula: see text]Hz) serve as novel electroencephalography (EEG) markers of epileptic tissue. The differentiation of physiological and epileptic HFO is an important challenge and is complicated by the fact that both types are generated in mesiotemporal structures. This study aimed to identify oscillation features that serve to distinguish physiological ripples associated with sleep spindles and epileptic ripples. We studied 19 patients with chronic intracranial EEG(iEEG) with mesiotemporal implantation and simultaneous scalp EEG. Sleep spindles, ripples and spikes were visually marked during nonrapid eye movement sleep stage 2. Ripples co-occurring with spikes and in seizure onset zone (SOZ) channels but outside of spindles were considered epileptic. The SOZ is defined by the origin of clinical seizures in iEEG. Ripples co-occurring with spindles were considered as models for physiological ripples. A correlation analysis showed a significant ripple amplitude peak - spindle trough - coupling, thus proving their physiological linkage. Epileptic ripples showed significantly higher values in all amplitude features than spindle ripples. All amplitude features and peaks per sample length showed a predictive value for the classification between model physiological ripples and epileptic ripples but indicate that the specificity is not sufficient for a reliable discrimination of single ripple events. The presented results suggest that a secure identification of epileptic ripples may be available to help identify the epileptic focus in the future.
Hemiconvulsion-Hemiplegia-Epilepsy Syndrome.
![]() |
| By Novaksean - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=44348140 |
J Pediatr. 2016 Dec 30;:
An interesting case of a 4-year-old boy with a history of epilepsy presented with multiple seizures and subsequent hemiparesis. He was found by his parents in the early morning having a tonic-clonic convulsion. He was febrile at that time, and the episode resolved within 10 minutes, with return to normal baseline.
PET MRI Coregistration in Intractable Epilepsy and Gray Matter Heterotopia.
Seniaray N, Jain A
Clin Nucl Med. 2016 Dec 30;:
A 25-year-old woman with intractable seizures underwent FDG PET/MRI for seizure focus localization. MRI demonstrated bilateral carpetlike nodular subependymal gray matter and asymmetrical focal dilatation in the right temporal horn. PET/MRI showed increased FDG within subependymal gray matter with significant hypometabolism in right anterior temporal lobe. EEG and ictal semiology confirmed the right temporal seizure origin. This case highlights the importance of identification of gray matter heterotopia on FDG PET/MRI.
Clin Nucl Med. 2016 Dec 30;:
A 25-year-old woman with intractable seizures underwent FDG PET/MRI for seizure focus localization. MRI demonstrated bilateral carpetlike nodular subependymal gray matter and asymmetrical focal dilatation in the right temporal horn. PET/MRI showed increased FDG within subependymal gray matter with significant hypometabolism in right anterior temporal lobe. EEG and ictal semiology confirmed the right temporal seizure origin. This case highlights the importance of identification of gray matter heterotopia on FDG PET/MRI.
A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment.
Huber B, Schmid G
Epilepsy Behav. 2016 Dec 27;66:74-79
The objective of this work was to review systematically the efficacy and tolerability of perampanel (PER) in residential patients of an epilepsy center.
We adopted an industry-independent noninterventional retrospective evaluation on the basis of the paper and electronic records complemented by personal information on the part of the treating neurologists. All patients (N=26, 15 females, mean age: 30, range 21-55years) started on PER from its introduction to the market in September 2012 until December 15th 2013 were included. Evaluation was carried out after 6, 12, and 24months of PER treatment. Changes in seizure frequency were calculated as the number of seizures during three months on PER compared to a three-month baseline period. The Clinical Global Impression Scale served as an instrument to record changes in seizure intensity beyond numerical values. Adverse effects were documented by means of the Liverpool Adverse Events Profile.
Most patients had structural or metabolic epilepsy, 2 patients suffered from Lennox-Gastaut syndrome, 2 from other symptomatic generalized epilepsy. All patients had grade III drug-resistant epilepsy. All patients had additional cognitive deficits of different degree. The retention rates were 61.5% after 6months, 46.2% after 12months, and 42.3% after 24months. The responder rates were 11.5% after 6months, 23.1% after 12months, and 7.7% after 24months. Partial responders (positive CGI and/or seizure reduction <50%) included, the respective values were 26.9%, 38.5%, and 23.1%. Only 1 patient was seizure free at 12months (but not at 24months). A loss of efficacy in the second year of treatment was suspected but the decrease of the responder rate could also be ascribed to a number of different circumstances. Adverse effects in the psychiatric field like irritability, aggression, increased sensitivity, and suicidal ideation/behavior occurred in 50% of the patients. They were the main reason to discontinue PER.
After one year of treatment PER showed reasonable efficacy in a particularly difficult-to-treat population. Psychiatric adverse effects forced discontinuation in many cases.
Morbidity and mortality of childhood- and adolescent-onset epilepsy: A controlled national study.
Jennum P, Pickering L, Christensen J, Ibsen R, Kjellberg J
Epilepsy Behav. 2016 Dec 27;66:80-85
Epilepsy is associated with significant morbidities and mortality. We aimed to evaluate the 30-year morbidities and mortality in a national group of patients after a first diagnosis of epilepsy.
From the Danish National Patient Registry (NPR), in total, 3123 patients with epilepsy aged 0-5years and 5018 patients aged 6-20years diagnosed in 1998-2002 were identified and compared with, respectively, 6246 and 10,036 persons matched for age, gender, and place of living with randomly chosen citizens from the Danish Civil Registration System Statistics. In the NPR, all morbidities in the following 30years were grouped into major WHO disease classes.
Patients with epilepsy had significantly higher rates of comorbidities including almost all health-related comorbidities compared with controls. Mortality rates were elevated: the hazard ratio (5%; 95% CI) was 14.46 (11.8; 17.7, p<0.001) and 5.58 (4.9; 6.4, P<0.001) for patients aged 0-5years and 6-20years at first diagnosis of epilepsy, respectively.
Epilepsy is associated with significant comorbidities and mortality including all health care domains, especially among persons who were young at the onset of epilepsy.
Electroencephalography: An Introductory Text and Atlas of Normal and Abnormal Findings
The
first known neurophysiologic recordings of animals were performed by Richard
Caton in 1875. The advent of recording the electrical activity of human beings
took another half century to occur. Hans Berger, a German psychiatrist,
pioneered the EEG in humans in 1924. The EEG is an electrophysiological
technique for the recording of electrical activity arising from the human
brain. Given its exquisite temporal sensitivity, the main utility of EEG is in
the evaluation of dynamic cerebral functioning. EEG is particularly useful for
evaluating patients with suspected seizures, epilepsy, and unusual spells. With
certain exceptions, practically all patients with epilepsy will demonstrate
characteristic EEG alterations during an epileptic seizure (ictal, or during-seizure,
recordings). Most epilepsy patients also show characteristic interictal (or
between-seizure) epileptiform discharges (IEDs) termed spike (<70 µsec
duration), spike and wave, or sharp-wave (70–200 µsec duration) discharges.
Free Book...Prolonged exposure therapy for the treatment of patients diagnosed with psychogenic non-epileptic seizures (PNES) and post-traumatic stress disorder (PTSD).
Myers L, Vaidya-Mathur U, Lancman M
Epilepsy Behav. 2016 Dec 27;66:86-92
OBJECTIVE: Although there is general consensus that psychogenic non-epileptic seizures (PNES) are treated with psychotherapy, the effectiveness of most psychotherapeutic modalities remains understudied. In this treatment series of 16 patients dually diagnosed with PNES and post-traumatic stress disorder (PTSD), we evaluated the effect of prolonged exposure therapy (PE) on reduction of PNES. Secondary measures included Beck Depression Inventory (BDI-II) and Post-Traumatic Disorder Diagnostic Scale (PDS).
METHODS: Subjects diagnosed with video EEG-confirmed PNES and PTSD confirmed through neuropsychological testing and clinical interview were treated with traditional PE psychotherapy with certain modifications for the PNES. Treatment was conducted over the course of 12-15 weekly sessions. Seizure frequency was noted in each session by examining the patients' seizure logs, and mood and PTSD symptomatology was assessed at baseline and on the final session.
RESULTS: Eighteen subjects enrolled, and 16 (88.8%) completed the course of treatment. Thirteen of the 16 (81.25%) therapy completers reported no seizures by their final PE session, and the other three reported a decline in seizure frequency (Z=-3.233, p=0.001). Mean scores on scales of depression (M=-13.56, SD=12.27; t (15)=-4.420, p<0,001) and PTSD symptoms (M=-17.1875, SD=13.01; t (15)=-5.281, p<0.001) showed significant improvement from baseline to final session. Longitudinal seizure follow up in 14 patients revealed that gains made on the final session were maintained at follow-up (Z=-1.069 p=0.285).
SIGNIFICANCE: Prolonged exposure therapy for patients dually diagnosed with PNES and PTSD reduced the number of PNES and improved mood and post traumatic symptomatology. Follow-up revealed that gains made in seizure control on the last day of treatment were maintained over time.
Managing epilepsy-associated depression: Serotonin enhancers or serotonin producers?
Singh T, Goel RK
Epilepsy Behav. 2016 Dec 27;66:93-99
Depression is one of the major psychiatric comorbidities having a major impact on the quality of life in people with epilepsy (PWE). Selective serotonin reuptake inhibitors (SSRIs) are considered as safest therapy for the treatment of depression in PWE. Although administration of SSRIs increases the synaptic serotonin levels, it decreases the overall serotonin synthesis in the brain. Long-term therapy with SSRIs has been reported to decrease serotonin synthesis, which may be the possible reason for lessening of their antidepressant effect over time as well as elevated seizure outcomes observed in PWE. Thus the present scenario warrants streamlined studies to explore the safety and efficacy of SSRIs as well as approaches beyond SSRIs for treatment of depression in epilepsy. In this review, we outline the approaches which may restore serotonin levels rather than a pseudo enhancement of serotonin with SSRIs. The potential of various anti-inflammatory approaches such as selective cyclooxygenase-2 inhibitors, inflammatory cytokine inhibitors, and indoleamine 2,3-dioxygenase inhibitors pertaining to their serotonin restoring effects is discussed as possible therapy for treatment of depression in epilepsy.
Subscribe to:
Posts (Atom)










